Q&A: From the CDC to Gilead Sciences, Rashad Burgess works local for national change in HIV community
The Covid pandemic set back progress in another pandemic, HIV, to devastating effect. Few likely know that as well as Rashad Burgess, the head of Gilead Sciences’ HIV community operations and overseeing the pharma company’s local ambassadors in cities across the US.
For the first time in 40 years, there were months when more people were dropping out of HIV treatment than enrolling, Burgess said. The prevalence is particularly pronounced in the South, which even before the pandemic accounted for 51% of new HIV diagnoses, according to the CDC – and its only gotten worse in the past 21 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
